Standard BioTools Inc. (LAB)

Standard BioTools' share price declined by 17.46% from April 7, 2025, to April 2, 2026, reaching new 52-week lows in early April 2026. The sale of SomaLogic to Illumina was completed on January 30, 2026, providing approximately $550 million in cash and investments. On February 24, 2026, the company reported Q4 and full-year 2025 financial results, with revenue from continuing operations at $23.8 million for Q4 and $85.3 million for the full year, operationalizing over $40 million in annualized cost savings, and reporting a net loss of $58.8 million for 2025. The company is repositioning as a pure-play tools provider following the SomaScan divestiture, emphasizing its core CyTOF, Hyperion, and Biomark franchises. As of September 2025, Standard BioTools had US$195 million in cash and a cash burn of US$98 million over the preceding year, indicating a cash runway of approximately 2.0 years.

Standard BioTools, Inc. experiences demand seasonality for its products and services. The company expects revenue in the range of $80 million to $85 million for fiscal year 2026, with seasonality similar to prior years.

Standard BioTools, Inc., formerly Fluidigm Corporation, is an American life science tools company that develops, manufactures, and sells instrumentation, consumables, and services to biomedical researchers. The company operates in the Life Sciences Tools and Services sector, focusing on discovery tools for healthcare. Standard BioTools provides insights into health and disease through mass cytometry and microfluidics technologies, serving applications in proteomics and genomics. Its major products and services include mass cytometry systems like the CyTOF XT and Hyperion XTi, genomic analysis instruments like the Biomark™ X9 System, associated consumables and reagents, and lab services offering high-plex protein and antibody profiling, single-cell analysis, spatial proteomics, custom conjugation services, and bioinformatics support.

Standard BioTools maintains a global presence with operations and support teams across several countries. In North America, it has offices and facilities in the USA (Boulder, Colorado; San Francisco, California) and Canada (Markham, Ontario). In Europe, it is present in France (Paris), the United Kingdom (London, Cambridge), the Netherlands (Amstelveen), Germany (Munich), and Italy (Milan). In Asia, it operates in China (Shanghai), Singapore, and Japan (Tokyo).

Standard BioTools, Inc., rebranded from Fluidigm Corporation in 2022, aims to accelerate breakthroughs in human health by delivering leading omics solutions. The company emphasizes its global support team and lab services, which are backed by a robust quality framework and scientific expertise. The sale of its SomaLogic business to Illumina in January 2026 has allowed Standard BioTools to refocus on its core mass cytometry and microfluidics platforms.

Standard BioTools Inc. has a significant institutional ownership base, with 164 institutional owners and shareholders holding a total of 302,828,133 shares as of April 10, 2026. Major institutional owners include Casdin Capital, LLC, Viking Global Investors Lp, BlackRock, Inc., Mak Capital One Llc, Vanguard Group Inc, Long Focus Capital Management, Llc, Morgan Stanley, Geode Capital Management, Llc, State Street Corp and Hollow Brook Wealth Management LLC. Casdin Capital and Viking Global were instrumental in a $250 million recapitalization of the company in December 2022.